Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2155863 | 0.86 | LMNA (0.37) | ACHEMAPTTDP1FOLH1ALDH1A1 | |
| SCHEMBL2155754 | 0.83 | MAPT (0.43) | ACHEMAPTFOLH1LMNA | |
| SCHEMBL2156425 | 0.79 | LMNA (0.37) | ACHEMAPTTDP1ALDH1A1NOTUM | |
| SCHEMBL2155323 | 0.78 | ACHE (0.36) | ACHEMAPTTDP1ALDH1A1NOTUM | |
| SCHEMBL2155804 | 0.77 | LMNA (0.44) | MAPTTDP1FOLH1ALDH1A1TSHR | |
| SCHEMBL2155997 | 0.75 | MAPT (0.44) | ACHEMAPTTDP1ALDH1A1LMNA | |
| SCHEMBL2156506 | 0.74 | FOLH1 (0.41) | MAPTFOLH1ALDH1A1TSHRLMNA | |
| SCHEMBL2156183 | 0.71 | MAPT (0.40) | ACHEMAPTTDP1ALDH1A1NOTUM | |
| SCHEMBL13871247 | 0.69 | MAPT (0.42) | ACHEMAPTTDP1LMNAHTT | |
| SCHEMBL2156058 | 0.68 | SMN1; SMN2 (0.40) | ACHEMAPTTDP1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | GRUENENTHAL GMBH (DE) | 2008-07-03 | — | — | US | claimed |
| US-7973072-B2 | Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example | GRUENENTHAL GMBH (DE) | 2011-07-05 | — | — | US | disclosed |
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | GRUENENTHAL GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161352-A1 | Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production | BCKDK, SYMPK, DHPS | ACHE 3986/4885MAPT 3287/4885TDP1 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.